Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection

详细信息    查看全文

• 作者：Ming Yang (1)
  Wanhong Xu (1)
  Melissa Goolia (1)
  Zhidong Zhang (1)
  
  1. National Centre for Foreign Animal Disease ; 1015 Arlington Street ; Winnipeg ; R3E 3 M4 ; Manitoba ; Canada
  
• 关键词：Foot ; and ; mouth disease ; Monoclonal antibody ; Antigenic site ; Vaccine matching
• 刊名：Virology Journal
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：11
• 期：1
• 全文大小：1,081 KB
• 参考文献：1. Kahn, S, Geale, DW, Kitching, PR, Bouffard, A, Allard, DG, Duncan, JR (2002) Vaccination against foot-and-mouth disease: the implications for Canada. Can Vet J 43: pp. 349-354
  2. Hutber, AM, Kitching, RP, Fishwick, JC, Bires, J (2011) Foot-and-mouth disease: the question of implementing vaccinal control during an epidemic. Vet J 188: pp. 18-23 CrossRef
  3. Barnett, PV (2001) Foot-and-mouth disease鈥搕he vaccine. Biologist (London) 48: pp. 55
  4. Paton, DJ, Valarcher, JF, Bergmann, I, Matlho, OG, Zakharov, VM, Palma, EL, Thomson, GR (2005) Selection of foot and mouth disease vaccine strains鈥揳 review. Rev Sci Tech 24: pp. 981-993
  5. Ahl, R, Haas, B, Lorenz, RJ, Wittmann, G (1990) Alternative potency test of FMD vaccines and results of comparative antibody assays in different cell systems and ELISA. Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Lindholm, Denmark, 25鈥?9 June. Food and Agriculture Organisation (FAO), Rome, pp. 51-60
  6. Rweyemamu, MM, Booth, JC, Head, M, Pay, TW (1978) Microneutralization tests for serological typing and subtyping of foot-and-mouth disease virus strains. J Hyg (Lond) 81: pp. 107-123 CrossRef
  7. Kitching, RP, Rendle, R, Ferris, NP (1988) Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease virus. Vaccine 6: pp. 403-408 CrossRef
  Foot and mouth disease. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Volume 2. Office international des 茅pizooties, Paris, pp. 145-173
  8. Mattion, N, Goris, N, Willems, T, Robiolo, B, Maradei, E, Beascoechea, CP, Perez, A, Smitsaart, E, Fondevila, N, Palma, E, De Clercq, K, La Torre, J (2009) Some guidelines for determining foot-and-mouth disease vaccine strain matching by serology. Vaccine 27: pp. 741-747 CrossRef
  9. Mattion, N, Konig, G, Seki, C, Smitsaart, E, Maradei, E, Robiolo, B, Duffy, S, Leon, E, Piccone, M, Sadir, A, Bottini, R, Cosentino, B, Falczuk, A, Maresca, R, Periolo, O, Bellinzoni, R, Espinoza, A, Torre, JL, Palma, EL (2004) Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease. Vaccine 22: pp. 4149-4162 CrossRef
  10. Crowther, JR, Farias, S, Carpenter, WC, Samuel, AR (1993) Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J Gen Virol 74 (Pt 8): pp. 1547-1553 CrossRef
  11. Crowther, JR, Reckziegel, PO, Prado, JA (1995) Quantification of whole virus particles (146S) of foot-and-mouth disease virus in the presence of virus subunits (12S), using monoclonal antibodies in a sandwich ELISA. Vaccine 13: pp. 1064-1075 CrossRef
  12. McCullough, KC, Crowther, JR, Carpenter, WC, Brocchi, E, Capucci, L, De Simone, F, Xie, Q, McCahon, D (1987) Epitopes on foot-and-mouth disease virus particles. I. Topology. Virology 157: pp. 516-525 CrossRef
  13. Van Maanen, C, Terpstra, C (1990) Quantification of intact 146S foot-and-mouth disease antigen for vaccine production by a double antibody sandwich ELISA using monoclonal antibodies. Biologicals 18: pp. 315-319 CrossRef
  14. Samuel, AR, Knowles, NJ, Samuel, GD, Crowther, JR (1991) Evaluation of a trapping ELISA for the differentiation of foot-and-mouth disease virus strains using monoclonal antibodies. Biologicals 19: pp. 299-310 CrossRef
  15. Seki, C, Robiolo, B, Periolo, O, Iglesias, M, D鈥橝ntuono, A, Maradei, E, Barros, V, La Torre, J, Mattion, N (2009) Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies. Vet Microbiol 133: pp. 239-251 CrossRef
  16. Mahapatra, M, Aggarwal, N, Cox, S, Statham, RJ, Knowles, NJ, Barnett, PV, Paton, DJ (2008) Evaluation of a monoclonal antibody-based approach for the selection of foot-and-mouth disease (FMD) vaccine strains. Vet Microbiol 126: pp. 40-50 CrossRef
  17. Yang, M, Clavijo, A, Suarez-Banmann, R, Avalo, R (2007) Production and characterization of two serotype independent monoclonal antibodies against foot-and-mouth disease virus. Vet Immunol Immunopathol 115: pp. 126-134 CrossRef
  18. Kitson, JD, McCahon, D, Belsham, GJ (1990) Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology 179: pp. 26-34 CrossRef
  19. Aggarwal, N, Barnett, PV (2002) Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species. J Gen Virol 83: pp. 775-782
  20. Rudreshappa, AG, Sanyal, A, Mohapatra, JK, Subramaniam, S, De, A, Das, B, Singanallur, NB, Jangam, AK, Muthukrishnan, M, Villuppanoor, SA, Pattnaik, B (2012) Emergence of antigenic variants with in serotype A foot and mouth disease virus in India and evaluation of a new vaccine candidate panel. Vet Microbiol 158: pp. 405-409 CrossRef
  21. Rweyemamu, MM (1984) Antigenic variation in foot-and-mouth disease: studies based on the virus neutralization reaction. J Biol Stand 12: pp. 323-337 CrossRef
  22. Pattnaik, B, Subramaniam, S, Sanyal, A, Mohapatra, JK, Dash, BB, Ranjan, R, Rout, M (2012) Foot-and-mouth disease: global status and future road map for control and prevention in India. Agric Res 1: pp. 132-147 CrossRef
  23. Yang, M, Berhane, Y, Salo, T, Li, M, Hole, K, Clavijo, A (2008) Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. J Virol Methods 147: pp. 265-274 CrossRef
  24. Briand, JP, Barin, C, Van Regenmortel, MH, Muller, S (1992) Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies. J Immunol Methods 156: pp. 255-265 CrossRef
  25. Barnett, PV, Ouldridge, EJ, Rowlands, DJ, Brown, F, Parry, NR (1989) Neutralizing epitopes of type O foot-and-mouth disease virus. I. identification and characterization of three functionally independent, conformational sites. J Gen Virol 70 ( Pt 6): pp. 1483-1491 CrossRef
  26. Barnett, PV, Samuel, AR, Pullen, L, Ansell, D, Butcher, RN, Parkhouse, RM (1998) Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse. J Gen Virol 79 ( Pt 7): pp. 1687-1697
  27. Maradei, E, Perez Beascoechea, C, Malirat, V, Salgado, G, Seki, C, Pedemonte, A, Bonastre, P, D鈥橝loia, R, La Torre, JL, Mattion, N, Rodriguez Toledo, J, Bergmann, IE (2011) Characterization of foot-and-mouth disease virus from outbreaks in Ecuador during 2009-2010 and cross-protection studies with the vaccine strain in use in the region. Vaccine 29: pp. 8230-8240 CrossRef
  28. Crowther, JR (1993) The use of monoclonal antibodies in the molecular typing of animal viruses. Rev Sci Tech 12: pp. 369-383
  29. Xie, QC, McCahon, D, Crowther, JR, Belsham, GJ, McCullough, KC (1987) Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol 68 ( Pt 6): pp. 1637-1647 CrossRef
  30. Jackson, T, Mould, AP, Sheppard, D, King, AM (2002) Integrin alphavbeta1 is a receptor for foot-and-mouth disease virus. J Virol 76: pp. 935-941 CrossRef
  31. Fox, G, Parry, NR, Barnett, PV, McGinn, B, Rowlands, DJ, Brown, F (1989) The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol 70 ( Pt 3): pp. 625-637 CrossRef
  32. Nagendrakumar, SB, Srinivasan, VA, Madhanmohan, M, Yuvaraj, S, Parida, S, Di Nardo, A, Horsington, J, Paton, DJ (2011) Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen. Vaccine 29: pp. 1906-1912 CrossRef
  33. Robiolo, B, La Torre, J, Maradei, E, Beascoechea, CP, Perez, A, Seki, C, Smitsaart, E, Fondevila, N, Palma, E, Goris, N, De Clercq, K, Mattion, N (2010) Confidence in indirect assessment of foot-and-mouth disease vaccine potency and vaccine matching carried out by liquid phase ELISA and virus neutralization tests. Vaccine 28: pp. 6235-6241 CrossRef
  34. McCullough, KC, Crowther, JR, Butcher, RN, Carpenter, WC, Brocchi, E, Capucci, L, De Simone, F (1986) Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology 58: pp. 421-428
  35. McCullough, KC, Bruckner, L, Schaffner, R, Fraefel, W, Muller, HK, Kihm, U (1992) Relationship between the anti-FMD virus antibody reaction as measured by different assays, and protection in vivo against challenge infection. Vet Microbiol 30: pp. 99-112 CrossRef
  36. McCullough, KC, De Simone, F, Brocchi, E, Capucci, L, Crowther, JR, Kihm, U (1992) Protective immune response against foot-and-mouth disease. J Virol 66: pp. 1835-1840
  37. Thomas, A, Woortmeijer, R, Barteling, S, Meloen, R (1988) Evidence for more than one important, neutralizing site on foot-and-mouth disease virus. Arch Virol 99: pp. 237-242 CrossRef
  38. Mateu, MG (1995) Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res 38: pp. 1-24 CrossRef
  39. Mahapatra, M, Hamblin, P, Paton, DJ (2012) Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals. J Gen Virol 93: pp. 488-493 CrossRef
  40. Dunn, CS, Samuel, AR, Pullen, LA, Anderson, J (1998) The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease. Virology 247: pp. 51-61 CrossRef
  41. Das, B, Sanyal, A, Subramaniam, S, Mohapatra, JK, Pattnaik, B (2012) Field outbreak strains of serotype O foot-and-mouth disease virus from India with a deletion in the immunodominant betaG-betaH loop of the VP1 protein. Arch Virol 157: pp. 1967-1970 CrossRef
  42. Rojas, ER, Carrillo, E, Schiappacassi, M, Campos, R (1992) Modification of foot-and-mouth disease virus O1 Caseros after serial passages in the presence of antiviral polyclonal sera. J Virol 66: pp. 3368-3372
  43. Feigelstock, D, Mateu, MG, Piccone, ME, De Simone, F, Brocchi, E, Domingo, E, Palma, EL (1992) Extensive antigenic diversification of foot-and-mouth disease virus by amino acid substitutions outside the major antigenic site. J Gen Virol 73 ( Pt 12): pp. 3307-3311 CrossRef
  44. Altshuler, E, Serebryanaya, D, Katrukha, A (2010) Generation of recombinant antibodies and means for increasing their affinity. Biochemistry (Moscow) 75: pp. 1584-1605 CrossRef
  45. Dinka, SK, Swaney, LM, Vicar, JW (1977) Selection of a stable clone of the MVPK-1 fetal porcine kidney cell for assays of foot-and-month disease virus. Can J Microbiol 23: pp. 295-299 CrossRef
  46. Hohlich, BJ, Wiesmuller, KH, Schlapp, T, Haas, B, Pfaff, E, Saalmuller, A (2003) Identification of foot-and-mouth disease virus-specific linear B-cell epitopes to differentiate between infected and vaccinated cattle. J Virol 77: pp. 8633-8639 CrossRef
  47. Yang, M, Clavijo, A, Li, M, Hole, K, Holland, H, Wang, H, Deng, MY (2007) Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications. J Immunol Methods 321: pp. 174-181 CrossRef
  48. Booth, JC, Rweyemamu, MM, Pay, TW (1978) Dose-response relationships in a microneutralization test for foot-and-mouth disease viruses. J Hyg (Lond) 80: pp. 31-42 CrossRef
  49. Martinez, HM (1983) An efficient method for finding repeats in molecular sequences. Nucleic Acids Res 11: pp. 4629-4634 CrossRef
  50. Lipman, DJ, Pearson, WR (1985) Rapid and sensitive protein similarity searches. Science 227: pp. 1435-1441 CrossRef
  51. Logan, D, Abu-Ghazaleh, R, Blakemore, W, Curry, S, Jackson, T, King, A, Lea, S, Lewis, R, Newman, J, Parry, N (1993) Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362: pp. 566-568 CrossRef
  52. Pettersen, EF, Goddard, TD, Huang, CC, Couch, GS, Greenblatt, DM, Meng, EC, Ferrin, TE (2004) UCSF Chimera鈥揳 visualization system for exploratory research and analysis. J Comput Chem 25: pp. 1605-1612 CrossRef
  
• 刊物主题：Virology;
• 出版者：BioMed Central
• ISSN：1743-422X

文摘

Background Foot-and-mouth disease (FMD) has severe implications for animal farming which leads to considerable financial losses because of its rapid spread, high morbidity and loss of productivity. For these reasons, the use of vaccine is often favoured to prevent and control FMD. Selection of the proper vaccine is extremely difficult because of the antigenic variation within FMDV serotypes. The aim of the current study was to produce a panel of mAbs and use it for the characterization of new isolates of FMDV serotype O. Results A panel of FMDV/O specific mAb was produced. The generated mAbs were then characterized using the peptide array and mAb resistant mutant selection. Seven out of the nine mAbs reacted with five known antigenic sites, thus the other two mAbs against non-neutralizing sites were identified. The mAbs were then evaluated by antigenic ELISA for the detection of forty-six FMDV serotype O isolates representing seven of ten known topotypes. Isolates ECU/4/10 and HKN/2/11 demonstrated the highest antigenic variation compared to the others. Furthermore, the panel of mAbs was used in vaccine matching by antigenic profiling ELISA with O1/Manisa as the reference strain. However, there was no correlation between vaccine matching by antigenic ELISA and the gold standard method, virus neutralisation test (VNT), for the forty-six FMDV/O isolates. Nine isolates had particularly poor correlation with the reference vaccine strain as revealed by the low r1 values in VNT. The amino acid sequences of the outer capsid proteins for these nine isolates were analyzed and compared with the vaccine strain O1/Manisa. The isolate ECU/4/10 displayed three unique amino acid substitutions around the antigenic sites 1, 3 and 4. Conclusions The panel of mAbs is useful to monitor the emergence of antigenically different strains and determination of relevant antigenic site differences. However, for vaccine matching VNT remains the preferred method but a combination of VNT, antigenic profiling with a panel of mAbs and genetic sequencing would probably be more ideal for full characterization of any new outbreak isolates as well as for selection of vaccine strains from FMDV antigen banks.